<DOC>
	<DOCNO>NCT02769104</DOCNO>
	<brief_summary>The investigator design study investigate effect aromatase inhibitor ( AI ) plus chemotherapy versus chemotherapy neoadjuvant treatment postmenopausal hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Aromatase Inhibitors Plus Chemotherapy v Chemotherapy Neoadjuvant Treatment Postmenopausal HR ( + ) Breast Cancer</brief_title>
	<detailed_description>The endocrine therapy use neoadjuvant treatment hormone receptor-positive breast cancer . But still question neoadjuvant endocrine therapy use combine chemotherapy . There several small-sample study concern item also get result support suppose endocrine therapy combine chemotherapy could rise effect neoadjuvant treatment . This study investigate effect aromatase inhibitor ( AI ) plus chemotherapy versus chemotherapy neoadjuvant treatment postmenopausal hormone receptor-positive breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>provision inform consent clinical stage IIA~IIIC histologically proven HR+ invasive breast cancer woman define postmenopausal accord NCCN guideline plan accept neoadjuvant ( pre operational ) chemotherapy treatment clinical evidence metastatic disease bilateral oophorectomy ; radiation ovaries patient , whatever reason ( e.g. , confusion , infirmity , alcoholism ) , unlikely comply trial requirement patient accepted anticancer treatment previous hormonal therapy adjuvant treatment noncancer disease patient unwilling stop take drug know affect sex hormonal status , would inappropriate stop previous history invasive malignancy within last 5 year , squamous basal cell carcinoma skin carcinoma situ cervix , adequately cone biopsied treatment nonapproved experimental drug 1 month entry study history bleed diathesis ( i.e. , Disseminated intravascular coagulation , clot factor deficiency ) , long term anticoagulant therapy ( antiplatelet therapy low dose warfarin ) leukopenia and/or thrombocytopenia history ocular fundus disease history thromboembolic diseases history osteoporotic fracture</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>aromatase inhibitor</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>breast cancer</keyword>
</DOC>